Human mesenchymal progenitor cell
First Claim
Patent Images
1. Isolated mesenchymal progenitor cells that are pluri-differentiated.
1 Assignment
0 Petitions
Accused Products
Abstract
Pluri-differentiated human mesenchymal progenitor cells (MPCs) are isolated. A method isolates and purifies human mesenchymal progenitor cells from Dexter-type cultures for characterization of and uses, particularly therapeutic uses for such cells. Specifically, isolated MPCs can be used for diagnostic purposes, to enhance the engraftment of hematopoietic progenitor cells, enhance bone marrow transplantation, or aid in the treatment or prevention of graft versus host disease.
-
Citations
22 Claims
-
1. Isolated mesenchymal progenitor cells that are pluri-differentiated.
-
2. A therapeutic composition comprising an isolated pluri-differentiated mesenchymal progenitor cells and a pharmaceutically acceptable carrier, wherein said isolated pluri-differentiated mesenchymal progenitor cells are present in an amount effective for treating a disease state in a mammal in need thereof.
-
3. A therapeutic composition comprising isolated pluri-differentiated mesenchymal progenitor cells and a pharmaceutically acceptable carrier, wherein said isolated pluri-differentiated mesenchymal progenitor cells are present in an amount effective to enhance hematopoietic progenitor cell engraftment in a mammal in need thereof.
-
4. A therapeutic composition comprising isolated pluri-differentiated mesenchymal progenitor cells and a pharmaceutically acceptable carrier, wherein said pluri-differentiated mesenchymal progenitor cells are present in an amount effective to treat GvHD in a mammal about to undergo bone marrow or organ transplantation or suffering from GvHD caused by bone marrow or organ transplantation.
-
5. A method for purifying pluri-differentiated mesenchymal progenitor cells comprising the steps of:
-
a) providing a cell culture preparation by the Dexter method;
b) treating the cells to obtain a cell suspension;
c) removing macrophages;
d) fractionating the cells; and
e) collecting the fraction of pluri-differentiated mesenchymal progenitor cells.
-
- 6. A method for enhancing bone marrow engraftment in a mammal in need thereof which comprises administering to the mammal (i) isolated pluri-differentiated mesenchymal progenitor cells and (ii) a bone marrow graft, wherein the isolated pluri-differentiated mesenchymal progenitor cells are administered in an amount effective to promote engraftment of the bone marrow in the mammal.
-
8. A gene in an MPC for detecting the presence of cancer or pre-cancer in a cell population.
- 10. A method for enhancing engraftment of cells in a mammal in need thereof which comprises administering to the mammal isolated pluri-differentiated mesenchymal progenitor cells wherein the isolated pluri-differentiated mesenchymal progenitor cells are administered in an amount effective to promote engraftment of the cells in the mammal.
-
14. A SCID mouse model for investigating MPC function.
-
15. Phenotypic cultured bone marrow stromal cells capable of being analyzed at single cell level.
- 16. A diagnostic test for screening for abnormalities of bone marrow stromal cells.
-
19. Stromal cells for use in combination with engraftment or other similar procedures for enhancing the effectiveness of the treatment.
-
20. A method for treating graft-versus-host disease (GvHD) in a mammal about to undergo bone marrow or organ transplantation or suffering from GvHD caused by bone marrow or organ transplantation, by administering to the mammal an effective amount of isolated pluri-differentiated mesenchymal progenitor cells.
-
21. A method for diagnosing a disease state comprising the steps of:
-
a) establishing gene expression patterns of normal state bone marrow derived isolated pluri-differentiated mesenchymal progenitor cells;
b) establishing gene expression patterns of various leukemic state bone marrow derived isolated pluri-differentiated mesenchymal progenitor cells;
c) identifying gene sets that are unique to a given state; and
d) comparing a profile of bone marrow derived isolated mesenchymal progenitor cell of unknown state to said gene sets.
-
-
22. A method for identifying therapeutic targets for treatment of hematopoietic function comprising the steps of:
-
a) determining the median gene expression profile of bone marrow isolated pluri-differentiated mesenchymal progenitor cells associated with each disease state of interest;
b) identifying gene groups that are up-regulated, down regulated, and common to each disease state; and
c) identifying gene sets that are unique to a given state.
-
Specification